Tweets
LNA043 - modified, recombinant human angiopoietin-like 3 (ANGPTL3) protein
⭐️proof of concept trial on patients with articular cartilage lesions
⭐️regeneration of damaged cartilage
⭐️treatment effect in cartilage volume
⭐️phase IIb pending
Abs#POS0277
#EULAR2021 @RheumNow
Robert B Chao, MD @doctorRBC ( View Tweet )
5 years 2 months ago
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
5 years 2 months ago
How does MTX affect kidney function/adverse events? Pre-specified analysis of DBRCT: MTX 15-20mg/wk (n=2391) vs. PBO (n=2395) both with folic acid over median f/u 23 months
✅We demonstrated kidney safety of MTX
⚡️⚡️Also a *suggestion* of LESS decline in eGFR for MTX than PBO https://t.co/SZXloLRmnj
Jeffrey Sparks MD MMSc @jeffsparks ( View Tweet )
5 years 2 months ago
Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
5 years 2 months ago
#EULAR2021 #6899 Dr. Hovius: "Erythema migrans is a clinical diagnosis. If you suspect it, you should not order tests, you should prescribe antibiotics to treat the disease." Remember serologies are negative in early disease!
@Rheumnow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
#EULAR2021 POS0105: Predictors of flare in SLE low disease activity state:
⭐️Ongoing glucocorticoid treatment
⭐️Ongoing immunosuppressant treatment
⭐️Anti-RNP antibody
@RheumNow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy?
⭐️Mean C3 ⬆️28% compared to 1st trimester
⭐️Mean C4 ⬆️ 11% compared to 1st trimester
@RheumNow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
#EULAR2021 POS0227 recs all patients try subQ MTX before bDMARD. Mirza et al: ⬆️ efficacy & ⬇️side effects with subQ.
May not be for all pts, but subQ ⬆️ efficacy than high-dose PO MTX. ⬇️ GI side effects, but ⬆️ ulcers/hair loss (use folate/leucovorin for this)
@RheumNow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
#EULAR2021 POS0230: TNFi changes intestinal microbiota in IBD-SpA
⬇️ Proteobacteria
⬆️Lachnospiraceae, Coprococcus
Does inflammatory changes by TNFi restore intestinal eubiosis and does this affect SpA outcomes?
@Rheumnow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
#EULAR2021 OP0291 proposes focus score of 4+ as prognostic factor for lymphoma risk in Sjogrens
Focus score 4+:
⬆️lymphoma risk
⬆️salivary gland swelling
⬆️autoantibodies
⬇️thyroiditis
Authors propose 4yr follow-up biopsy in all pts Focus score 4+.
@RheumNow
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
#EULAR2021 LB0001. Mavrilimumab (blocks GM-CSF alpha) phase2 trial in non-vented patients w/ #COVID19 :
⭐️⬇️ mortality and ventilation at day 29
⭐️61% reduction in death (HR 0.39)
⭐️No drug related SAEs, no dose-related AEs
@Rheumnow https://t.co/9UOi3xF7Re
Eric Dein @ejdein1 ( View Tweet )
5 years 2 months ago
